Sun Pharma Advanced Research Company Limited (SPARC) Share Price
NSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE232I01014
Key metrics
- Market Cap
- ₹6,520 Cr
- P/E Ratio
- 4.12
- EPS
- 48.82
- Book Value
- 41.26
- P/B Ratio
- 4.87
- ROE
- 116.01%
- ROCE
- 84.3%
- Debt / Equity
- 0.42
- Net Margin
- 3,967.49%
- Revenue Growth
- -45.45%
- Profit Growth
- 553.48%
- Dividend Yield
- —
- 52W High
- ₹289.00
- 52W Low
- ₹108.00
- Market Cap Band
- mid cap
- Face Value
- 1
Ratios computed from the annual results period ending 2026-03-31.
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited engages in the research and development of pharmaceutical products in India and internationally. It develops Sezaby, a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium injection for the treatment of neonatal seizures; SPARC-121, a novel topical agent for the treatment of Alopecia Areata; and SPARC-122, an anti-MUC1 ADC for treatment of multiple cancer indications. The company is also involved in the development of PDP-716 for treatment of open-angle glaucoma. Sun Pharma Advanced Research Company Limited was incorporated in 2006 and is based in Mumbai, India.
- Headquarters
- Mumbai, India
- Employees
- 279
- Promoter Holding
- 75.12%
The full Sun Pharma Advanced Research Company Limited analysis
Create a free account to open the complete SPARC deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.